Summary
Iovance’s AMTAGVI has become the first personalized TIL therapy to receive regulatory clearance, gaining accelerated FDA approval for use in advanced melanoma following PD-1 inhibitor treatment.
AMTAGVI approval has sparked intensified activity across the field, with companies such as Obsidian Therapeutics (OBX-115), KSQ Therapeutics (KSQ-001EX, KSQ-004EX), Curacell Holding (CC-38), and Intima Bioscience (CISH-inactivated TIL), among others, advancing their own next-generation TIL candidates.
In addition to these therapies, Iovance is broadening its TIL pipeline with candidates such as LN-145, IOV-4001, and IOV-3001, while investigating combination t...
